

Felix MÃ¼ller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4589400/publications.pdf>

Version: 2024-02-01

39
papers

2,111
citations

304743

22
h-index

302126

39
g-index

40
all docs

40
docs citations

40
times ranked

1609
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. <i>Biological Psychiatry</i> , 2015, 78, 544-553.	1.3	340
2	LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality. <i>Neuropsychopharmacology</i> , 2016, 41, 2638-2646.	5.4	179
3	Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. <i>Neuropsychopharmacology</i> , 2020, 45, 462-471.	5.4	141
4	Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. <i>Neuropsychopharmacology</i> , 2021, 46, 537-544.	5.4	120
5	Altered network hub connectivity after acute LSD administration. <i>NeuroImage: Clinical</i> , 2018, 18, 694-701.	2.7	114
6	High Substrate Uptake Rates Empower <i>Vibrio natriegens</i> as Production Host for Industrial Biotechnology. <i>Applied and Environmental Microbiology</i> , 2017, 83, .	3.1	112
7	Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. <i>Psychopharmacology</i> , 2018, 235, 467-479.	3.1	91
8	Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. <i>Neuropsychopharmacology</i> , 2022, 47, 1180-1187.	5.4	72
9	Ecosystem Vulnerability Review: Proposal of an Interdisciplinary Ecosystem Assessment Approach. <i>Environmental Management</i> , 2018, 61, 904-915.	2.7	71
10	Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 461-466.	4.9	71
11	Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-blind, Placebo-controlled, Crossover Study in Healthy Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 886-895.	4.7	70
12	Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. <i>European Neuropsychopharmacology</i> , 2020, 41, 81-91.	0.7	62
13	Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1474-1483.	2.4	48
14	Neuroimaging of chronic MDMA (‘ecstasy’) effects: A meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 96, 10-20.	6.1	47
15	A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2021, 35, 398-405.	4.0	47
16	Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 138, 104689.	6.1	45
17	Polystyrene influences bacterial assemblages in <i>Arenicola marina</i> -populated aquatic environments in vitro. <i>Environmental Pollution</i> , 2016, 219, 219-227.	7.5	44
18	Neuroimaging in moderate MDMA use: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 62, 21-34.	6.1	40

#	ARTICLE	IF	CITATIONS
19	Alcohol acutely enhances decoding of positive emotions and emotional concern for positive stimuli and facilitates the viewing of sexual images. <i>Psychopharmacology</i> , 2017, 234, 41-51.	3.1	35
20	Comparative Effects of Methylphenidate, Modafinil, and MDMA on Response Inhibition Neural Networks in Healthy Subjects. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 712-720.	2.1	30
21	Role of the 5-HT _{2A} Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin. <i>Frontiers in Pharmacology</i> , 2021, 12, 711255.	3.5	30
22	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 658-666.	4.7	26
23	Quasideterministic transport of Brownian particles in an oscillating periodic potential. <i>Physical Review E</i> , 2010, 81, 061120.	2.1	22
24	Treatment of a Complex Personality Disorder Using Repeated Doses of LSD—A Case Report on Significant Improvements in the Absence of Acute Drug Effects. <i>Frontiers in Psychiatry</i> , 2020, 11, 573953.	2.6	22
25	Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States. <i>Frontiers in Psychiatry</i> , 2021, 12, 706017.	2.6	22
26	Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. <i>Psychopharmacology</i> , 2022, 239, 1933-1943.	3.1	22
27	A time projection chamber with GEM-based readout. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2017, 856, 109-118.	1.6	21
28	MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens. <i>Neuropsychopharmacology</i> , 2021, 46, 545-553.	5.4	21
29	Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. <i>Scientific Reports</i> , 2021, 11, 10851.	3.3	20
30	Comparative Untargeted Metabolomics Analysis of the Psychostimulants 3,4-Methylenedioxy-Methamphetamine (MDMA), Amphetamine, and the Novel Psychoactive Substance Mephedrone after Controlled Drug Administration to Humans. <i>Metabolites</i> , 2020, 10, 306.	2.9	19
31	Ensembles of excitable two-state units with delayed feedback. <i>Physical Review E</i> , 2010, 82, 061124.	2.1	18
32	Safety pharmacology of acute LSD administration in healthy subjects. <i>Psychopharmacology</i> , 2022, 239, 1893-1905.	3.1	18
33	Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain. <i>Progress in Brain Research</i> , 2018, 242, 159-177.	1.4	17
34	Acute Effects of Methylphenidate, Modafinil, and MDMA on Negative Emotion Processing. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 345-354.	2.1	16
35	Dosing Psychedelics and MDMA. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 3-21.	1.7	12
36	A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects. <i>Frontiers in Pharmacology</i> , 2017, 8, 423.	3.5	11

#	ARTICLE	IF	CITATIONS
37	Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2022, 7, 885-894.	1.5	8
38	Editorial: Hallucinogens and Entactogens: Establishing a New Class of Psychotherapeutic Drugs?. <i>Frontiers in Psychiatry</i> , 2020, 11, 497.	2.6	4
39	Acute effects of lysergic acid diethylamide (LSD) on resting brain function. <i>Swiss Medical Weekly</i> , 2019, 149, w20124.	1.6	3